Results 41 to 50 of about 1,989,151 (330)

SHP-1: the next checkpoint target for cancer immunotherapy? [PDF]

, 2016
The immense power of the immune system is harnessed in healthy individuals by a range of negative regulatory signals and checkpoints. Manipulating these checkpoints through inhibition has resulted in striking immune-mediated clearance of otherwise ...
Ager, Elizabeth, Matthews, James, Watson, Heulwen Angharad, Wehenkel, Sophie   +3 more
core   +3 more sources

The Proliferative Role of Immune Checkpoints in Tumors: Double Regulation

Cancers, 2022
Simple Summary Cancer remains a serious health problem owing to its high morbidity and mortality. Immunotherapy, represented by anti-programmed death-1D1/anti-PD-Ligand 1 treatments, has become one of the most important methods for cancer treatment ...
Xiyang Tang, Zhong-Lin Luo, Yanyan Xiong, Jie Yang, Anqi Shi, Kai-Fu Zheng, Yujian Liu, Chen Shu, N. Ma, Q. Lu, Jin-bo Zhao   +10 more
semanticscholar   +1 more source

The regulation of immune checkpoints by the hypoxic tumor microenvironment

PeerJ, 2021
The tumor microenvironment (TME) influences the occurrence and progression of tumors, and hypoxia is an important characteristic of the TME. The expression of programmed death 1 (PD1)/programmed death-ligand 1 (PDL1), cytotoxic T-lymphocyte-associated ...
Min Hu, Yongfu Li, Yuting Lu, Miao Wang, Yingrui Li, Chaoying Wang, Qin Li, Hong Zhao   +7 more
semanticscholar   +1 more source

NK Cell-Based Immune Checkpoint Inhibition

Frontiers in Immunology, 2020
Immunotherapy, with an increasing number of therapeutic dimensions, is becoming an important mode of treatment for cancer patients. The inhibition of immune checkpoints, which are the source of immune escape for various cancers, is one such ...
Muhammad Khan, Sumbal Arooj, Hua Wang
doaj   +1 more source

Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes

Frontiers in Cell and Developmental Biology, 2023
Background: Lung adenocarcinoma (LUAD) is the most common variant of non–small cell lung cancer (NSCLC) across the world. Recently, the rapid development of immunotherapy has brought a new dawn for LUAD patients.
Linbin Hua, Jiyue Wu, Jiashu Ge, Xin Li, Bin You, Wei Wang, Bin Hu   +6 more
doaj   +1 more source

CTLA-4 and PD-1 ligand gene expression in epithelial thyroid cancers [PDF]

, 2018
The dysregulation of PD-1 ligands (PD-L1 and PD-L2) and CTLA-4 ligands (CD80 and CD86) represents a tumor strategy to escape the immune surveillance. Here, the expression of PD-L1, PD-L2, CD80 and CD86 was evaluated at mRNA level in 94 patients affected ...
Antonelli, Alessandro, Arcieri, Stefano, Baldini, Enke, Barollo, Susi, Carbotta, Giovanni, Catania, Antonio, Fallahi, Poupak, Mian, Caterina, Monti, Massimo, Palmieri, Andrea, Pironi, Daniele, Sorrenti, Salvatore, Tartaglia, Francesco, Tuccilli, Chiara, Ulisse, Salvatore, Vergine, Massimo   +15 more
core   +3 more sources

Immune Checkpoints and Inhibitors

Ankara Üniversitesi Tıp Fakültesi Mecmuası, 2019
Antigen-specific T cells encountering and responding to tumor cells are regulated by a variety of mechanisms including inhibitory receptors and regulatory T cells to prevent overexposure immune responses.
Özge Baş Aksu, Şule Şengül
doaj   +1 more source

DNA repair: Disorders [PDF]

, 2010
No description ...
Bose, Burg, Caldecott, Chu, Digweed, Fernandez-Capetillo, Fousteri, Fousteri, Friedberg, Gudmundsdottir, Hashimoto, Hoeijmakers, Jiricny, Kraemer, Lavin, Lehmann, Lieber, Ma, Masutani, McCulloch, Meindl, Moldovan, Moshous, Nance, Nouspikel, O'Driscoll, O'Driscoll, O'Driscoll, O'Driscoll, Rass, Stefanini, Stewart, Stracker, Taylor, Vaz, Wu, Zlatanou   +36 more
core   +1 more source

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? [PDF]

, 2019
Background: The immune response in melanoma patients is locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk, nonbrisk, and absent.
Badalamenti G., Bazan V., Fanale D., Fulfaro F., Incorvaia L., Iovanna J. L., Olive D., Rinaldi G., Russo A., Swayden M., Terruso L., Vincenzi B.   +11 more
core   +1 more source

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Nature Communications, 2016
Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to these therapies has increasingly been observed.
S. Koyama, Esra A. Akbay, Yvonne Y. Li, G. Herter-Sprie, Kevin A. Buczkowski, W. Richards, L. Gandhi, A. Redig, S. Rodig, H. Asahina, Robert E. Jones, Meghana Kulkarni, M. Kuraguchi, Sangeetha Palakurthi, P. Fecci, B. Johnson, P. Jänne, J. Engelman, Sidharta P. Gangadharan, D. Costa, G. Freeman, R. Bueno, F. Hodi, G. Dranoff, Kwok-kin Wong, Peter S. Hammerman, Peter S. Hammerman   +26 more
semanticscholar   +1 more source